NASDAQ
BBI

Brickell Biotech Inc

Biotechnology & Medical Research
Healthcare

Prices are adjusted according to historical splits.

Brickell Biotech Inc Stock Price

Vitals

Today's Low:
$0.59
Today's High:
$0.628
Open Price:
$0.59
52W Low:
$0.4495
52W High:
$7.875
Prev. Close:
$0.59
Volume:
31164

Company Statistics

Market Cap.:
$6.75 million
Book Value:
5.812
Revenue TTM:
$4.64 million
Operating Margin TTM:
-657.53%
Gross Profit TTM:
$-27827000
Profit Margin:
0%
Return on Assets TTM:
-80.2%
Return on Equity TTM:
-157.29%

Company Profile

Brickell Biotech Inc had its IPO on 1993-03-15 under the ticker symbol BBI.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Brickell Biotech Inc has a staff strength of 16 employees.

Stock update

Shares of Brickell Biotech Inc opened at $0.59 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.59 - $0.63, and closed at $0.6.

This is a +1.71% increase from the previous day's closing price.

A total volume of 31,164 shares were traded at the close of the day’s session.

In the last one week, shares of Brickell Biotech Inc have slipped by -3.37%.

Brickell Biotech Inc's Key Ratios

Brickell Biotech Inc has a market cap of $6.75 million, indicating a price to book ratio of 0.4099 and a price to sales ratio of 1.4546.

In the last 12-months Brickell Biotech Inc’s revenue was $4.64 million with a gross profit of $-27827000 and an EBITDA of $-30502000. The EBITDA ratio measures Brickell Biotech Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Brickell Biotech Inc’s operating margin was -657.53% while its return on assets stood at -80.2% with a return of equity of -157.29%.

In Q2, Brickell Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 2757.6%.

Brickell Biotech Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.42 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Brickell Biotech Inc’s profitability.

Brickell Biotech Inc stock is trading at a EV to sales ratio of 1063.4404 and a EV to EBITDA ratio of 0.2799. Its price to sales ratio in the trailing 12-months stood at 1.4546.

Brickell Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.51 million
Total Liabilities
$2.87 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Brickell Biotech Inc ended 2024 with $18.51 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.51 million while shareholder equity stood at $15.64 million.

Brickell Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $2.87 million in other current liabilities, 1211000.00 in common stock, $-155924000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.48 million and cash and short-term investments were $14.48 million. The company’s total short-term debt was $36,000 while long-term debt stood at $0.

Brickell Biotech Inc’s total current assets stands at $18.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $510000.00 compared to accounts payable of $1.26 million and inventory worth $0.

In 2024, Brickell Biotech Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Brickell Biotech Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.6
52-Week High
$7.875
52-Week Low
$0.4495
Analyst Target Price
$5

Brickell Biotech Inc stock is currently trading at $0.6 per share. It touched a 52-week high of $7.875 and a 52-week low of $7.875. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $0.68 and 200-day moving average was $1.08 The short ratio stood at 0.62 indicating a short percent outstanding of 0%.

Around 121% of the company’s stock are held by insiders while 1307.5% are held by institutions.

Frequently Asked Questions About Brickell Biotech Inc

The stock symbol (also called stock or share ticker) of Brickell Biotech Inc is BBI

The IPO of Brickell Biotech Inc took place on 1993-03-15

Similar Industry Stocks (Biotechnology & Medical Research)

Last Price
Chg
Chg%
$437.35
-24.55
-5.32%
VARDHMAN POLYTEX LTD. (VARDMNPOLY)
$61.9
-1.11
-1.76%
$118.9
-2.7
-2.22%
$2.01
-0.04
-1.95%
$152.8
-11.05
-6.74%
$31.35
-1.65
-5%
$36.32
-0.35
-0.95%
$2752
91.25
+3.43%
$84
-0.36
-0.43%
Ardelyx Inc (ARDX)
$4.83
0.1
+2.11%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Address

5777 Central Avenue, Boulder, CO, United States, 80301